JENBURKT Jenburkt Pharmaceuticals Limited

Regd. Office : UNICORN, 14th Floor, Dattaji Salvi Marg, Off Veera Desai Road, Andheri West, Mumbai 400 053. Phone: 022-67 603 603

Ref. No. JPL/CS/2371/2026 Date: 3rd November, 2026.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Script Code : 524731

Sub.: **Outcome of Board Meeting held today, i.e. 3rd November, 2026 –Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026.**

Reg.: **Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Dear Sir,

1. The Standalone Unaudited Financial Statements for the quarter and half year ended on 30th September, 2026 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide their meeting held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, along with statement of standalone Assets & Liabilities as at 30th September, 2026 and Cash Flow statement for the half year ended on 30th September, 2026, as annexure A and B respectively.

2. The Limited Audit Review Report dated 3rd November, 2026, of Auditors of the Company, on the standalone unaudited financial results for the quarter ended on 30th September, 2026, is also attached.

The Board Meeting commenced at 2.30 p.m. and was concluded at 05.20 p.m.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,

JENBURKT PHARMACEUTICALS LTD. MUMBAI

ASHISH R. SHAH
Sr. Vice President and Company Secretary.

Encl.: As Stated Above.

JENBURKT

Jenburkt Pharmaceuticals Limited

UNICORN, 14th Floor, Dattaji Salvi Marg, Off Veera Desai Road, Andheri West, Mumbai 400 053. Phone: 022-67 603 603

Statement of Standalone Unaudited Financial Results for the Quarter & Half Year Ended on 30th September, 2026

(₹. in Lacs other than EPS)

	Particulars	Quarter Ended			Year to Date		Year Ended
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	**Revenue from Operations**	4831.82	3551.20	4555.76	8383.02	8108.44	16874.06
II	**Other Income**	225.26	151.32	207.90	376.58	413.61	1029.94
III	**Total income (I + II)**	**5057.08**	**3702.52**	**4763.66**	**8759.60**	**8522.05**	**17904.00**
IV	**Expenses**						
(a)	Cost of Materials Consumed	195.65	231.59	219.35	427.24	432.89	899.35
(b)	Purchase of Stock-in-trade	719.96	547.84	628.33	1267.80	1165.57	2817.89
(c)	Changes in inventories of Finished Goods, Stock-in-trade and WIP	79.01	-147.24	-12.04	-68.23	-111.06	-484.67
(d)	Employee benefit expenses	1487.44	1302.52	1393.25	2789.96	2565.33	4988.22
(e)	Finance Costs	12.97	13.02	10.74	25.99	21.73	46.20
(f)	Depreciation and Amortisation Expense	79.89	64.07	74.39	143.96	146.64	310.76
(g)	Other expenses	1048.21	1013.81	1016.44	2062.02	1849.55	4279.25
	Total Expenses (IV)	**3623.13**	**3025.61**	**3330.46**	**6648.74**	**6070.65**	**12857.00**
V	**Profit before exceptional items and tax (III-IV)**	**1433.95**	**676.91**	**1433.20**	**2110.86**	**2451.40**	**5047.00**
VI	Exceptional items						
	Impact of Labour Codes #	0.00	0.00	0.00	0.00	0.00	395.11
VII	**Profit before tax (V-VI)**	**1433.95**	**676.91**	**1433.20**	**2110.86**	**2451.40**	**4651.89**
VIII	**Tax Expense**						
(i)	Current Tax	350.00	100.00	400.00	450.00	600.00	1260.00
(ii)	Income Tax for previous years	0.00	0.00	0.00	0.00	0.00	4.10
(iii)	Deferred Tax	63.01	-11.65	16.86	51.36	55.88	-85.81
IX	**Profit/(Loss) after Tax (VII-VIII)**	**1020.94**	**588.56**	**1016.34**	**1609.50**	**1795.52**	**3473.60**
X	**Other Comprehensive Income**						
A	(i) Items that will not be reclassified to profit or loss	-64.20	163.76	-45.10	99.56	110.09	-171.20
	(ii) Income Tax relatiing to Items that will not be reclassified to profit or loss	7.34	-13.51	16.97	-6.17	-0.79	18.30
B	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relatiing to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XI	**Total Comprehensive Income for the period (IX+X)**	**964.08**	**738.81**	**988.21**	**1702.89**	**1904.82**	**3320.70**
	Paid up Equity Share Capital (F.V. Rs.10/- each)	**441.33**	**441.33**	**441.33**	**441.33**	**441.33**	**441.33**
XII	**Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted**	**23.13**	**13.34**	**23.03**	**36.47**	**40.68**	**78.71**

Notes:

1 The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 3rd November, 2026.

2 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.

3 The Statement of Assets and Liablilites as at 30th Septemeber 2026 and Cashflow Statement for the half year ended 30th Septemeber 2026 are annexed as Annexure A & B respectively.

4 # The Government of India notified the Revised Labour Codes on November 21, 2025, resulting in an increase of ₹395.11 lakhs in gratuity and leave liabilities due to past service costs arising from plan amendments in FY 2025-26.

For Jenburkt Pharmaceuticals Limited

(Ashish U. Bhuta)
Chairman & Managing Director
(DIN No: 00226479)

Place : Mumbai
Date : 3rd November, 2026

JENBURKT PHARMACEUTICALS LTD. (MUMBAI)

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Annexure - A

Statement of Standalone Assets & Liabilities

JENBURKT

₹ in Lacs

			Particulars	30/09/2026	31/03/2026
				Amount	Amount
			ASSETS		
(1)			Non-current Assets		
	(a)		Property, Plants & Equipments	6564.34	1130.41
	(b)		Right to Use Asset	760.57	791.63
	(c)		Other Intangible assets	27.98	24.14
	(d)		Capital Work In Progress	328.27	4611.93
	(e)		Financial Assets		
		(i)	Investments	1939.58	2702.37
		(ii)	Loans	0.10	0.70
		(iii)	Other Financial Assets	1439.43	3466.07
			Deferred Tax Asset	250.45	239.90
	(f)		Other Non-current Assets	85.89	125.16
(2)			Current assets		
	(a)		Inventories	1509.74	1363.31
	(b)		Financial Assets		
		(i)	Investments	1062.04	0.00
		(ii)	Trade Receivables	1982.56	2435.69
		(iii)	Cash and Cash Equivalents	602.60	557.71
		(iv)	Bank Balance other than (iii)	6486.48	4753.74
		(v)	Loans	33.31	6.34
		(vi)	Other Financial Assets	66.48	39.80
	(c)		Other Current Assets	272.97	336.53
			Current Tax Asset (Net)	78.77	15.81
			Total Assets	**23,491.58**	**22,601.26**
			EQUITY AND LIABILITIES		
(1)			**Equity**		
	(a)		Equity Share Capital	441.33	441.33
	(b)		Other Equity - Reserves & Surplus	20,052.02	19,262.69
			Liabilities		
(2)			Non-current liabilities		
	(a)		Financial Liabilities		
		(i)	Lease Liabilities	154.63	183.95
		(ii)	Other Financial Liabilities	301.03	301.03
	(b)		Deferred Tax Liability	165.68	97.59
(3)			Current Liabilities		
	(a)		Financial Liabilities		
		(i)	Lease Liabilities	70.59	64.87
		(ii)	Trade Payables		
		(A)	Total Outstanding dues of Micro Enterprises and Small Enterprises; and	27.93	27.48
		(B)	Total Outstanding dues of creditors other than Micro Enterprises and Small Enterprises.	753.21	782.47
		(iv)	Other Financial Liabilities	441.78	539.83
	(b)		Other Current Liabilities	334.40	126.96
	(c)		Provisions #	748.97	659.26
	(d)		Current Tax Liabilities (Net)	-	113.80
			Total Equity and Liabilities	**23,491.58**	**22,601.26**

Note

The Government of India notified the Revised Labour Codes on November 21, 2025, resulting in an increase of ₹395.11 lakhs in gratuity and leave liabilities due to past service costs arising from plan amendments in FY 2025-26.

By order of the Board

For Jenburkt Pharmaceuticals Limited

JENBURKT PHARMACEUTICALS LTD. MUMBAI

(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

(DIN No: 00226479)

Place : Mumbai

Date : 3rd November, 2026

JENBURKT

Annexure - B

Cashflow Statement for the year ended 30th September, 2026

Rs in Lacs

				30-09-2026	31-03-2026
A.			**CASH FLOW FROM OPERATING ACTIVITIES :**		
	a		**Net Profit After Tax**	**1,609.50**	**3,473.60**
			Adjustments for :		
		i	Depreciation and Amortisation Expense	143.96	310.77
		ii	Loss on Fixed Assets scrapped	(1.03)	4.52
		iii	Tax Expense	501.36	1,178.29
		iv	Finance Cost	25.99	46.20
		v	Interest Income	(291.78)	(558.88)
		vi	Dividend income	(12.43)	(15.77)
		vii	Unrealsied Gain on Investment at Fair Value	(0.34)	(15.12)
		viii	Gain on sale of investment (Short Term Capital Gain / Loss)	(26.16)	(37.46)
		ix	Provision/write off for doubtful trade receivables/advances	(24.19)	(186.77)
		x	Unrealised Foreign Exchange gain	(27.94)	(71.08)
		xi	Others	1.12	1.97
			Operating profit (Loss) before working capital changes	**1,898.06**	**4,130.27**
	b		**MOVEMENTS IN WORKING CAPITAL**		
		i	Increase or (Decrease) in Inventories	(146.43)	(475.29)
		ii	Increase or (Decrease) in Trade Receivables	505.27	(104.35)
		iii	Increase or (Decrease) in Other (Current & Non Current) Assets	(64.10)	70.23
		iv	Increase or (Decrease) in Trade Payables	(28.80)	(5.58)
		v	Increase or (Decrease) in Bank Borrowings	-	(197.88)
		vi	Increase or (Decrease) in Other (Current & Non Current) Liabilities	118.64	29.19
		vii	Current & Non Current Financial Loans	(26.37)	0.06
		viii	Increase or (Decrease) in Provisions	89.71	384.43
	c		**Cash used in operation**	**2,345.98**	**3,831.07**
		i	Income Taxes paid (Net of Refund)	(626.76)	(1,178.89)
			Net cash used in operating activities (A)	**1,719.22**	**2,652.18**
B.			**CASH FLOW FROM INVESTING ACTIVITIES :**		
		i	Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in Development)	(1,120.34)	(1,371.71)
		ii	Proceeds from disposal of property, plant and equipment and intangible assets	2.50	0.82
		ii	Purchase of Investments	(1,841.51)	(3,912.20)
		iii	Proceeds from Sale / Redemption of Investments	1,668.32	3,261.43
		iv	Other Bank balances not considered as cash and cash equivalents		
			- Bank Fixed Deposit made during the year	(4,423.05)	(11,045.37)
			- Bank Fixed Deposit matured during the year	4,875.68	10,944.41
		v	Interest Received	146.33	161.82
		vi	Dividend Received	12.43	15.77
			Net cash generated by investing activities (B)	**(679.64)**	**(1,945.03)**
C.			**CASH FLOW FROM FINANCING ACTIVITIES :**		
		i	Finance Cost	(24.37)	(27.98)
		ii	Dividend paid	(927.29)	(793.94)
		iii	Repayment of Lease Liabilites	(43.03)	(63.99)
			Net cash used in financing activities (C)	**(994.69)**	**(885.92)**
			NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)	**44.89**	**(178.77)**
			Cash and cash equivalent at the beginning of the year (1st April, 2025)	557.71	736.48
			Cash and cash equivalent as at the end of the year (31st March, 2026)	602.60	557.71
				44.89	**(178.77)**

By order of the Board

For Jenburkt Pharmaceuticals Limited

JENBURKT PHARMACEUTICALS LTD. MUMBAI

(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

(DIN No: 00226479)

Place : Mumbai

Date : 3rd November, 2026

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034
TEL: 23513758 / 23520330 FAX: 66607263, 9322508373
Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30th September 2026 (the statement).

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)

D.R. MEHTA & ASSOCIATES * CHARTERED ACCOUNTANTS * M. NO. 106207W MUMBAI

Partner
Vikram Mehta
(Membership No. 047347)
UDIN: 26047347QITR107558
Place: Mumbai
Date: 3rd November 2026